Watch your wealth rise with the power of AI research tools only with TradeZing PLUS!
Subscribe NowTrade together with legendary hedge fund manager Larry Benedict every morning before the bell
What is Trade the Day?
Get ahead of the market curve each trading day with Larry Benedict, a distinguished Barron’s Top 100 hedge fund manager and the founder of the Opportunistic Trader ETF (WZRD). With his analyst, Eric Shamilov, Larry provides live, pre-market trading insights and strategic analysis, equipping you with the knowledge to make smart trading decisions.
Subscribe now for exclusive advantages and benefits!
May 9, 2024
13 mins ago
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company’s obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Company will no longer be a public reporting company and its obligations to file other reports with the SEC will also be suspended.
178226
News
May 9, 2024
13 mins ago
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
178225
News
May 9, 2024
13 mins ago
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.
178230
News
Copied
May 9, 2024
13 mins ago
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company’s obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Company will no longer be a public reporting company and its obligations to file other reports with the SEC will also be suspended.
ADXS
178226
News
May 9, 2024
13 mins ago
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GYRE
178225
News
May 9, 2024
13 mins ago
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.
ANAB
178230
News
Introducing Audio Rooms: Engage in real-time discussions on community or news topics with fellow users. Each article or post can instantly create its exclusive audio room, facilitating conversations about subjects directly tied to the article or community post.
Audio Room Title:
Someone already created an audio of this feed.
Join the room
Seeking Alpha
Bezinga
Market Rebellion
Motley Fool
And More!
Subscribe now for exclusive advantages and benefits!
0 Comments